Prognostic value of Caveolin-1 in patients treated with radical prostatectomy

a multicentric validation study

Romain Mathieu, Tobias Klatte, Ilaria Lucca, Aurélie Mbeutcha, Christian Seitz, Pierre I. Karakiewicz, Harun Fajkovic, Maxine Sun, Yair Lotan, Douglas S. Scherr, Francesco Montorsi, Alberto Briganti, Morgan Rouprêt, Vitaly Margulis, Michael Rink, Luis A. Kluth, Malte Rieken, Lukas Kenner, Martin Susani, Brian D. Robinson & 3 others Evanguelos Xylinas, Wolgang Loidl, Shahrokh F. Shariat

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective: To validate Caveolin-1 as an independent prognostic marker of biochemical recurrence (BCR) in a large multi-institutional cohort of patients with prostate cancer treated with radical prostatectomy (RP). Patients and Methods: Caveolin-1 expression was evaluated by immunochemistry on a tissue microarray in 3 117 patients treated with RP for prostate cancer at five institutions. Univariable and multivariable Cox proportional hazards regression models assessed the association of Caveolin-1 status with BCR. Harrell's c-index quantified prognostic accuracy. Results: Caveolin-1 was overexpressed in 644 (20.6%) patients and was associated with higher pathological Gleason sum (P = 0.002) and lymph node metastases (P = 0.05). Within a median (interquartile range) follow-up of 38 (21–66) months, 617 (19.8%) patients experienced BCR. Patients with overexpression of Caveolin-1 had worse BCR-free survival than those with normal expression (log-rank test, P = 0.004). Caveolin-1 was an independent predictor of BCR in multivariable analyses that adjusted for the effects of standard clinicopathological features (hazard ratio 1.21, P = 0.037). Addition of Caveolin-1 in a model for prediction of BCR based on these standard prognosticators did not significantly improve the predictive accuracy of the model. In subgroup analyses, Caveolin-1 was associated with BCR in patients with favourable pathological features (pT2pN0 and Gleason score = 6; P = 0.021). Conclusions: We confirmed that overexpression of Caveolin-1 is associated with adverse pathological features in prostate cancer and independently predicts BCR after RP, especially in patients with favourable pathological features. However, it did not add prognostically relevant information to established predictors of BCR, limiting its use in clinical practice.

Original languageEnglish (US)
Pages (from-to)243-249
Number of pages7
JournalBJU International
Volume118
Issue number2
DOIs
StatePublished - Aug 1 2016

Fingerprint

Caveolin 1
Validation Studies
Prostatectomy
Recurrence
Prostatic Neoplasms
Immunochemistry
Neoplasm Grading
Proportional Hazards Models
Biomarkers
Lymph Nodes
Neoplasm Metastasis
Survival

Keywords

  • Caveolin
  • disease recurrence
  • prognosis
  • prostate cancer
  • radical prostatectomy

ASJC Scopus subject areas

  • Urology

Cite this

Mathieu, R., Klatte, T., Lucca, I., Mbeutcha, A., Seitz, C., Karakiewicz, P. I., ... Shariat, S. F. (2016). Prognostic value of Caveolin-1 in patients treated with radical prostatectomy: a multicentric validation study. BJU International, 118(2), 243-249. https://doi.org/10.1111/bju.13224

Prognostic value of Caveolin-1 in patients treated with radical prostatectomy : a multicentric validation study. / Mathieu, Romain; Klatte, Tobias; Lucca, Ilaria; Mbeutcha, Aurélie; Seitz, Christian; Karakiewicz, Pierre I.; Fajkovic, Harun; Sun, Maxine; Lotan, Yair; Scherr, Douglas S.; Montorsi, Francesco; Briganti, Alberto; Rouprêt, Morgan; Margulis, Vitaly; Rink, Michael; Kluth, Luis A.; Rieken, Malte; Kenner, Lukas; Susani, Martin; Robinson, Brian D.; Xylinas, Evanguelos; Loidl, Wolgang; Shariat, Shahrokh F.

In: BJU International, Vol. 118, No. 2, 01.08.2016, p. 243-249.

Research output: Contribution to journalArticle

Mathieu, R, Klatte, T, Lucca, I, Mbeutcha, A, Seitz, C, Karakiewicz, PI, Fajkovic, H, Sun, M, Lotan, Y, Scherr, DS, Montorsi, F, Briganti, A, Rouprêt, M, Margulis, V, Rink, M, Kluth, LA, Rieken, M, Kenner, L, Susani, M, Robinson, BD, Xylinas, E, Loidl, W & Shariat, SF 2016, 'Prognostic value of Caveolin-1 in patients treated with radical prostatectomy: a multicentric validation study', BJU International, vol. 118, no. 2, pp. 243-249. https://doi.org/10.1111/bju.13224
Mathieu, Romain ; Klatte, Tobias ; Lucca, Ilaria ; Mbeutcha, Aurélie ; Seitz, Christian ; Karakiewicz, Pierre I. ; Fajkovic, Harun ; Sun, Maxine ; Lotan, Yair ; Scherr, Douglas S. ; Montorsi, Francesco ; Briganti, Alberto ; Rouprêt, Morgan ; Margulis, Vitaly ; Rink, Michael ; Kluth, Luis A. ; Rieken, Malte ; Kenner, Lukas ; Susani, Martin ; Robinson, Brian D. ; Xylinas, Evanguelos ; Loidl, Wolgang ; Shariat, Shahrokh F. / Prognostic value of Caveolin-1 in patients treated with radical prostatectomy : a multicentric validation study. In: BJU International. 2016 ; Vol. 118, No. 2. pp. 243-249.
@article{4fda32f153174d54a9cab28001a28b39,
title = "Prognostic value of Caveolin-1 in patients treated with radical prostatectomy: a multicentric validation study",
abstract = "Objective: To validate Caveolin-1 as an independent prognostic marker of biochemical recurrence (BCR) in a large multi-institutional cohort of patients with prostate cancer treated with radical prostatectomy (RP). Patients and Methods: Caveolin-1 expression was evaluated by immunochemistry on a tissue microarray in 3 117 patients treated with RP for prostate cancer at five institutions. Univariable and multivariable Cox proportional hazards regression models assessed the association of Caveolin-1 status with BCR. Harrell's c-index quantified prognostic accuracy. Results: Caveolin-1 was overexpressed in 644 (20.6{\%}) patients and was associated with higher pathological Gleason sum (P = 0.002) and lymph node metastases (P = 0.05). Within a median (interquartile range) follow-up of 38 (21–66) months, 617 (19.8{\%}) patients experienced BCR. Patients with overexpression of Caveolin-1 had worse BCR-free survival than those with normal expression (log-rank test, P = 0.004). Caveolin-1 was an independent predictor of BCR in multivariable analyses that adjusted for the effects of standard clinicopathological features (hazard ratio 1.21, P = 0.037). Addition of Caveolin-1 in a model for prediction of BCR based on these standard prognosticators did not significantly improve the predictive accuracy of the model. In subgroup analyses, Caveolin-1 was associated with BCR in patients with favourable pathological features (pT2pN0 and Gleason score = 6; P = 0.021). Conclusions: We confirmed that overexpression of Caveolin-1 is associated with adverse pathological features in prostate cancer and independently predicts BCR after RP, especially in patients with favourable pathological features. However, it did not add prognostically relevant information to established predictors of BCR, limiting its use in clinical practice.",
keywords = "Caveolin, disease recurrence, prognosis, prostate cancer, radical prostatectomy",
author = "Romain Mathieu and Tobias Klatte and Ilaria Lucca and Aur{\'e}lie Mbeutcha and Christian Seitz and Karakiewicz, {Pierre I.} and Harun Fajkovic and Maxine Sun and Yair Lotan and Scherr, {Douglas S.} and Francesco Montorsi and Alberto Briganti and Morgan Roupr{\^e}t and Vitaly Margulis and Michael Rink and Kluth, {Luis A.} and Malte Rieken and Lukas Kenner and Martin Susani and Robinson, {Brian D.} and Evanguelos Xylinas and Wolgang Loidl and Shariat, {Shahrokh F.}",
year = "2016",
month = "8",
day = "1",
doi = "10.1111/bju.13224",
language = "English (US)",
volume = "118",
pages = "243--249",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Prognostic value of Caveolin-1 in patients treated with radical prostatectomy

T2 - a multicentric validation study

AU - Mathieu, Romain

AU - Klatte, Tobias

AU - Lucca, Ilaria

AU - Mbeutcha, Aurélie

AU - Seitz, Christian

AU - Karakiewicz, Pierre I.

AU - Fajkovic, Harun

AU - Sun, Maxine

AU - Lotan, Yair

AU - Scherr, Douglas S.

AU - Montorsi, Francesco

AU - Briganti, Alberto

AU - Rouprêt, Morgan

AU - Margulis, Vitaly

AU - Rink, Michael

AU - Kluth, Luis A.

AU - Rieken, Malte

AU - Kenner, Lukas

AU - Susani, Martin

AU - Robinson, Brian D.

AU - Xylinas, Evanguelos

AU - Loidl, Wolgang

AU - Shariat, Shahrokh F.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Objective: To validate Caveolin-1 as an independent prognostic marker of biochemical recurrence (BCR) in a large multi-institutional cohort of patients with prostate cancer treated with radical prostatectomy (RP). Patients and Methods: Caveolin-1 expression was evaluated by immunochemistry on a tissue microarray in 3 117 patients treated with RP for prostate cancer at five institutions. Univariable and multivariable Cox proportional hazards regression models assessed the association of Caveolin-1 status with BCR. Harrell's c-index quantified prognostic accuracy. Results: Caveolin-1 was overexpressed in 644 (20.6%) patients and was associated with higher pathological Gleason sum (P = 0.002) and lymph node metastases (P = 0.05). Within a median (interquartile range) follow-up of 38 (21–66) months, 617 (19.8%) patients experienced BCR. Patients with overexpression of Caveolin-1 had worse BCR-free survival than those with normal expression (log-rank test, P = 0.004). Caveolin-1 was an independent predictor of BCR in multivariable analyses that adjusted for the effects of standard clinicopathological features (hazard ratio 1.21, P = 0.037). Addition of Caveolin-1 in a model for prediction of BCR based on these standard prognosticators did not significantly improve the predictive accuracy of the model. In subgroup analyses, Caveolin-1 was associated with BCR in patients with favourable pathological features (pT2pN0 and Gleason score = 6; P = 0.021). Conclusions: We confirmed that overexpression of Caveolin-1 is associated with adverse pathological features in prostate cancer and independently predicts BCR after RP, especially in patients with favourable pathological features. However, it did not add prognostically relevant information to established predictors of BCR, limiting its use in clinical practice.

AB - Objective: To validate Caveolin-1 as an independent prognostic marker of biochemical recurrence (BCR) in a large multi-institutional cohort of patients with prostate cancer treated with radical prostatectomy (RP). Patients and Methods: Caveolin-1 expression was evaluated by immunochemistry on a tissue microarray in 3 117 patients treated with RP for prostate cancer at five institutions. Univariable and multivariable Cox proportional hazards regression models assessed the association of Caveolin-1 status with BCR. Harrell's c-index quantified prognostic accuracy. Results: Caveolin-1 was overexpressed in 644 (20.6%) patients and was associated with higher pathological Gleason sum (P = 0.002) and lymph node metastases (P = 0.05). Within a median (interquartile range) follow-up of 38 (21–66) months, 617 (19.8%) patients experienced BCR. Patients with overexpression of Caveolin-1 had worse BCR-free survival than those with normal expression (log-rank test, P = 0.004). Caveolin-1 was an independent predictor of BCR in multivariable analyses that adjusted for the effects of standard clinicopathological features (hazard ratio 1.21, P = 0.037). Addition of Caveolin-1 in a model for prediction of BCR based on these standard prognosticators did not significantly improve the predictive accuracy of the model. In subgroup analyses, Caveolin-1 was associated with BCR in patients with favourable pathological features (pT2pN0 and Gleason score = 6; P = 0.021). Conclusions: We confirmed that overexpression of Caveolin-1 is associated with adverse pathological features in prostate cancer and independently predicts BCR after RP, especially in patients with favourable pathological features. However, it did not add prognostically relevant information to established predictors of BCR, limiting its use in clinical practice.

KW - Caveolin

KW - disease recurrence

KW - prognosis

KW - prostate cancer

KW - radical prostatectomy

UR - http://www.scopus.com/inward/record.url?scp=84978476940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978476940&partnerID=8YFLogxK

U2 - 10.1111/bju.13224

DO - 10.1111/bju.13224

M3 - Article

VL - 118

SP - 243

EP - 249

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 2

ER -